Home - Australian Pharmacist

Research winners for PSA18

Sharon Smith - August 1, 2018

Lauren Corre from University of South Australia accepting the Best Poster Prize

Industry

Researchers examining polypharmacy within aged populations have won the best paper and best poster categories at PSA18. Lauren Corre and a team of University of...

NOW IS THE TIME – nominate to help PSA support, promote,...

Dr Fei Sim FPS BPharm (Hons) PhD FHEA GAICD FPS - February 15, 2023

The President of the Pharmaceutical Society

Industry

The 2023 PSA General Elections are coming up, and we are on the lookout for motivated pharmacists to lead the profession.

What pharmacists can learn from rural and remote practice

Jennifer Cooke - July 27, 2019

Industry

Rural and remote practice for pharmacists should be regarded as a ‘seeding ground’ to drive pharmacist’s practice that can then be integrated back into...

Managing gastrointestinal problems in infants

John Bell AM FPS - September 17, 2019

Clinical

Opting for a better approach. Proton pump inhibitors (PPIs) were developed in the 1980s. Omeprazole, the first to be marketed, is on the WHO Model...

Safe hands: minimising antipsychotic use in the elderly

Thea Cowie - April 29, 2019

Clinical

Concerns over the overuse of antipsychotics in Residential Aged Care Facilities have reached a high tide – but so have efforts to address the...

PSA names new CEO

AP Staff - October 16, 2019

Industry

The PSA board has appointed health care advocate and health policy expert Mark Kinsela as its new Chief Executive Officer. Mr Kinsela was appointed after...

1...241242243...318 Page 242 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch